Cargando…
Activity of daily living in mucopolysaccharidosis IVA patients: Evaluation of therapeutic efficacy
BACKGROUND: Mucopolysaccharidosis IVA (MPS IVA, also called Morquio A syndrome) is caused by a deficiency of N‐acetylglucosamine‐6‐sulfate sulfatase (GALNS) and results in skeletal dysplasia symptoms such as short stature and abnormal gait. Treatments include enzyme replacement therapy (ERT) and hem...
Autores principales: | Chen, Hui, Khan, Shaukat, Celik, Betul, Suzuki, Yasuyuki, Ago, Yasuhiko, Tomatsu, Shunji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606213/ https://www.ncbi.nlm.nih.gov/pubmed/34623762 http://dx.doi.org/10.1002/mgg3.1806 |
Ejemplares similares
-
Bone Growth Induction in Mucopolysaccharidosis IVA Mouse
por: Rintz, Estera, et al.
Publicado: (2023) -
Long-term therapeutic efficacy of allogenic bone marrow transplantation in a patient with mucopolysaccharidosis IVA()
por: Chinen, Yasutsugu, et al.
Publicado: (2014) -
Mucopolysaccharidosis IVA: Diagnosis, Treatment, and Management
por: Sawamoto, Kazuki, et al.
Publicado: (2020) -
Mucopolysaccharidosis IVA: Current Disease Models and Drawbacks
por: Leal, Andrés Felipe, et al.
Publicado: (2023) -
Pathophysiology of Hip Disorders in Patients with Mucopolysaccharidosis IVA
por: Wang, Zhigang, et al.
Publicado: (2020)